Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research.
The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization.
Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting and pricing benchmarks.
Trinity then ran a pipeline assessment to predict shifts within the landscape and evolution in P&MA benchmarks, and synthesized findings to deliver a comprehensive indication-by-indication achievable net pricing strategy for early P&MA forecasting inputs.
- Detailed XLS outlining current pricing and access status of competitor therapies including level of contracting and payer mix
- Pipeline analysis including likely price comparator, achievable net price and likely level of payer management
Project Outcomes & Impact
The key P&MA data that Trinity provided to inform inputs for the early P&MA forecast of the client’s pipeline asset enabled them to prioritize their development activities and launch strategy to optimize the commercial opportunity.
Closing the Gap: Reflections on the 2023 Milken Institute Future of Health Summit
Introduction The Trinity team recently attended the Milken Institute’s 2023 Future of Health Summit in Washington, DC. Its theme was “Closing the Gap” in healthcare – as chronic disease becomes more prevalent worldwide and the average life expectancy in the US declines to its lowest level since the early 1990’s, what can be done? The […]
Elevating Commercialization in China Part 2: The Key to Pricing and Access Optimization
Available On Demand
In Part 1 of this webinar series, The Path to Launch, we discussed various pathways and innovative programs to accelerate product launch in China. However, launching a product is only half of the battle. Ensuring optimal access to deliver the treatment to more patients is also critical for commercial success. Join Trinity Life Sciences’ APAC experts […]
What Lies Ahead for New Product Launches?
Trinity Life Sciences has been tracking and analyzing the challenges of commercialization and new product launches in the Biopharma industry for years (see our 2022 white paper, Empowering the Next-Generation Launch Model). One method we have leveraged to track the challenges in commercialization is new product launch performance, comparing first calendar year actual sales with […]